Edition:
United Kingdom

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

11.39USD
14 Dec 2018
Change (% chg)

$0.21 (+1.88%)
Prev Close
$11.18
Open
$11.14
Day's High
$11.50
Day's Low
$10.96
Volume
206,437
Avg. Vol
292,517
52-wk High
$32.15
52-wk Low
$10.10

Latest Key Developments (Source: Significant Developments)

Momenta Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Friday, 7 Dec 2018 

Dec 6 (Reuters) - :MOMENTA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.MOMENTA PHARMACEUTICALS- PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 17,391,305 SHARES OF ITS COMMON STOCK AT PUBLIC OFFERING PRICE OF $11.50 PER SHARE.  Full Article

Momenta Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 5 Dec 2018 

Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MOMENTA PHARMACEUTICALS INC - IS COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING.  Full Article

Momenta Pharma says Q3 loss per share $0.44
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc -:Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $24.1 million versus $29.1 million.Q3 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.44.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Momenta Pharmaceuticals - co and Mylan are targeting a first regulatory submission for clinical development of M710 by early 2018​.Momenta Pharmaceuticals - ‍updated non-GAAP operating expense guidance of about $200 million - $210 million for 2017 and $43 million - $53 million for Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍expects to recognize $50 million upfront payment from CSL as revenue in Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍estimates that collaborative reimbursement revenues will be approximately $0 - $2 million in Q4 of 2017​.  Full Article

Momenta And Mylan report initial results from phase 1 clinical trial for M834
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc :Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept).Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​.Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​.  Full Article